Articles related to DRUG SAFETY & INTERACTIONS

Ensure patient safety and treatment efficacy with awareness of the recent recall of omeprazole and sodium bicarbonate powder, essential for treating critical gastrointestinal conditions.

In oncology, the balance between rapid innovation and patient safety is critical. The recent withdrawal of an accelerated approval cancer drug highlights the need for more stringent evidence and robust trial design to truly benefit patients.

The POLARIX trial reveals polatuzumab vedotin with R-CHP as a promising first-line therapy for DLBCL, showing a 27% reduction in the risk of progression, relapse, or death and a progression-free survival rate of 76.7% at 2 years.

With more than 27,000 doses administered, CAR T-cell therapies represent a breakthrough in treating hematologic malignancies, though emerging reports of secondary T-cell cancers post-treatment highlight the importance of long-term patient monitoring and reporting.

In a comprehensive analysis of COPD patients, the use of gabapentinoids was found to be associated with a 1.39 times higher risk of severe exacerbations requiring hospitalization. This finding underscores the need for cautious prescribing of these medications in the COPD population, considering their potential respiratory risks.

Explore the vital link between EHR usability and patient safety. Recent data from 112 US hospitals reveals a significant correlation, emphasizing the need for improved usability to enhance medication safety.